All participants – Page 15 – Communicable Diseases Research

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

C형 간염 바이러스 감염 임산부에 대한 레디파스비르 + 소포스부비르: 1상 약동학 연구

Article

Published on 2020-08-132022-09-06
Journal: The Lancet. Microbe [Category] Communicable Disease,

Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada

Letter

Published on 2020-07-142022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 Activation age All participants anticipated baseline blinded block sizes blocked blood sample Canada Chloroquine circulating cirrhosis clinical clinician composite endpoint computer-generated Concomitant medication correlation Course COVID-19 COVID-19 negative criteria deficiency determine diabete diagnostic disease severity dissemination ECG element Encephalopathy endothelial Enrollment extension FIVE fixed Follow-up G6PD HCQ HCW Health care worker Hepatitis high risk hospital Hospitalization Hospitalized Host Hydroxychloroquine immune include individually randomized insulin intensive care units Intervention intervention arm intubation investigator Laboratory Liver disease Long marker microbiologically Mortality multisite neutralize non-invasive ventilation non-specific number objective offered Older open label Oropharyngeal outcome outcome measure parallel-group participant patients per day Placebo placebo-controlled plasma porphyria positive positive result pregnant Prevent Primary outcome Prophylaxis Protecting protocol Psychological distress psychological Impact QTc QTc interval randomised randomised placebo controlled trial reactive reduce Registered renal reported Research Respiratory failure risk of COVID-19 Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus secondary Seroconversion serology Standard status study period Study protocol Support symptom duration symptomatic syndrome Tablet tablets term Toronto Trial two group Two-arm undergo use of hydroxychloroquine ventilator viral PCR Viral RNA website worker
[DOI] 10.1186/s13063-020-04577-8 PMC 바로가기 [Article Type] Letter

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

후보 중동 호흡기 증후군 코로나바이러스 바이러스 매개 백신의 안전성 및 면역원성: 용량 증량, 공개, 비무작위, 비통제, 1상 시험

Article

Published on 2020-07-012022-08-13
Journal: The Lancet. Infectious Diseases [Category] 임상,

[키워드] absence adverse event AID All participant All participants antibody Antigen Arabian Peninsula assigned baseline cellular cellular and humoral immunogenicity cellular response ChAdOx1 ChAdOx1 MERS clinical clinical development clinical trial coronavirus Department described dose dose-escalation doses effective elicit ELISA enzyme enzyme-linked immunospot expressing finding FIVE Follow-up follow-up period full-length full-length spike surface glycoprotein funding healthy hepatitis B hepatitis B surface antigen hepatitis C hepatitis C antibodies hepatitis C antibody High-dose high-dose group HIV antibodies humans humoral humoral immunogenicity IgG immunogenicity ImmunoSpot Infection interferon interferon-γ-linked enzyme-linked immunospot intermediate-dose group Intervention Intramuscular injection low-dose Medicine MERS MERS-CoV MERS-CoV spike antigen Middle East Middle East respiratory syndrome Coronavirus Mild mild in severity moderate neutralisation neutralisation assay Neutralising Antibodies nine Occurrence Open-label Oxford participant Phase 1 phase 1 trial pre-vaccination test pre-vaccination tests pregnancy test progression proportion Pseudotyped virus public health Registered Relative risk reported resolved respiratory respiratory syndrome coronavirus response risk Safe Safety Saudi Arabia Serious Adverse Event Serious Adverse Events severe adverse event significant increase significantly higher simian adenovirus-vectored vaccine single dose Support surface antigen Surface glycoprotein T-cell tested Tolerability trials tropical medicine urinary pregnancy test vaccination vectored vaccine Viral viral particle Viral particles virus neutralising assay virus neutralising assays was done women
[DOI] 10.1016/S1473-3099(20)30160-2 PMC 바로가기 [Article Type] Article

Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial

비경구 3가 P2-VP8 소단위 로타바이러스 백신의 안전성 및 면역원성: 다중 부위, 무작위, 이중 맹검, 위약 대조 시험

Article

Published on 2020-07-012022-09-06
Journal: The Lancet. Infectious Diseases [Category] Communicable Disease,

[키워드] adjusted Adults adverse event adverse events African age All participants analysed Antigen assigned baseline block block size block sizes blocks blood sample Blood samples Comparisons death Deltoid muscle dose dose-escalation double-blind Efficacy elicited eligible enrolment evaluate febrile febrile convulsion Final finding FIVE foundation funding geometric mean geometric mean titre gestation GRADE group groups HIV infection IgA IgG IgG seroresponse IgG seroresponses immunogenic immunogenicity immunogenicity endpoint Infant Infants injection Injections Intramuscular injection Laboratory Local Melinda Gate Melinda Gates Meningitis multisite neutralising antibody neutralising antibody response Neutralising antibody responses neutralising antibody seroresponse neutralising antibody seroresponses no significant difference no significant differences occurred parent parents participant Participants Placebo placebo group placebo recipient placebo recipients placebo-controlled placebo-controlled trial pneumococcal pneumococcal meningitis protocol randomisation randomised Randomly receive recipient Registered Research respiratory Respiratory tract infections response responses against rotavirus vaccination rotavirus vaccine Safety safety endpoint Serious Adverse Event Serious Adverse Events serum significantly higher South South Africa Strains subunit Support systemic adverse events systemic reaction systemic reactions the placebo group the vaccine timepoints Treatment Trial trivalent USA Vaccine was done were assessed
[DOI] 10.1016/S1473-3099(20)30001-3 PMC 바로가기 [Article Type] Article

Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial

HIV에 감염된 임산부에서 3가 비활성화 인플루엔자 백신의 다양한 투여 일정의 면역원성과 안전성: 무작위 대조 시험

Article

Published on 2020-01-032022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] age All participants analysed Antenatal Antibody Response assigned Birth clinics completion computer-generated Controlled trial dose dosing schedule double-blind eligible ENhance enrolled enrolment estimated gestational age except for Final finding foundation Frequency funding gestational age greater group Group allocation HIV immunogenic immunogenicity Immunogenicity analyses immunogenicity analysis inactivated induce Infant Infants Influenza influenza vaccine Local Melinda Gate Melinda Gates mother Neonates Newborn newborn infants outcome participant pregnant women protective antibodies Protective antibody randomisation list randomised randomised controlled trial Randomly reaction receive recipient recipients recruited regimen Registered Safety Seasonal influenza seroconversion rate seroconversion rates Seven significantly higher single dose Single-dose South Africa Standard-dose strain Strains systemic reactions the vaccine three groups transfer trivalent Vaccine vaccine dose were measured with HIV women
[DOI] 10.1016/S2352-3018(19)30322-4 PMC 바로가기 [Article Type] Article